Sarepta Therapeutics Reports Positive Clinical Results from Phase 2 MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
Go back to Sarepta Therapeutics Reports Positive Clinical Results from Phase 2 MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51| SAREPTA THERAP (NASDAQ: SRPT) | Delayed: 22.10 +1.16 (5.54%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $20.94 | 52 Week High | $63.73 | |||
| Open | $20.81 | 52 Week Low | $8.00 | |||
| Day High | $23.22 | P/E | N/A | |||
| Day Low | $20.63 | EPS | $-5.69 | |||
| Volume | 2,837,841 | |||||
